CA2621236A1 - Host cell lines for production of antibody constant region with enhanced effector function - Google Patents

Host cell lines for production of antibody constant region with enhanced effector function Download PDF

Info

Publication number
CA2621236A1
CA2621236A1 CA002621236A CA2621236A CA2621236A1 CA 2621236 A1 CA2621236 A1 CA 2621236A1 CA 002621236 A CA002621236 A CA 002621236A CA 2621236 A CA2621236 A CA 2621236A CA 2621236 A1 CA2621236 A1 CA 2621236A1
Authority
CA
Canada
Prior art keywords
antibody
cell line
cell
cells
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002621236A
Other languages
English (en)
French (fr)
Inventor
Haimanti Dorai
Yun Seung Kyung
Bernard Scallon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2621236A1 publication Critical patent/CA2621236A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
CA002621236A 2005-08-31 2006-08-31 Host cell lines for production of antibody constant region with enhanced effector function Abandoned CA2621236A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71305505P 2005-08-31 2005-08-31
US71285805P 2005-08-31 2005-08-31
US60/712,858 2005-08-31
US60/713,055 2005-08-31
PCT/US2006/034382 WO2007028106A2 (en) 2005-08-31 2006-08-31 Host cell lines for production of antibody constant region with enhanced effector function

Publications (1)

Publication Number Publication Date
CA2621236A1 true CA2621236A1 (en) 2007-03-08

Family

ID=37809622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002621236A Abandoned CA2621236A1 (en) 2005-08-31 2006-08-31 Host cell lines for production of antibody constant region with enhanced effector function

Country Status (9)

Country Link
US (1) US20090214528A1 (enExample)
EP (1) EP1937313A4 (enExample)
JP (1) JP2009508476A (enExample)
KR (1) KR20080048505A (enExample)
AU (1) AU2006287224A1 (enExample)
BR (1) BRPI0616600A2 (enExample)
CA (1) CA2621236A1 (enExample)
MX (1) MX2008003054A (enExample)
WO (1) WO2007028106A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2763768A1 (en) * 2009-05-29 2010-12-02 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
SG10201407983VA (en) * 2009-12-18 2015-01-29 Csl Ltd Method of purifying polypeptides
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
HUE035887T2 (en) 2012-12-05 2018-05-28 Alnylam Pharmaceuticals Inc PCSK9 iRNA preparations and methods for their use
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
AU2015267052A1 (en) * 2014-05-27 2016-12-15 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN108348541A (zh) * 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
IL268007B2 (en) * 2017-01-30 2025-05-01 Janssen Biotech Inc Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
AU2017398101B2 (en) * 2017-02-07 2025-02-06 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
JP2021518854A (ja) * 2019-05-08 2021-08-05 ノバルティス アーゲー Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4596046A3 (en) 2020-05-21 2025-10-22 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1079704A (en) 1912-06-19 1913-11-25 Dallas C Hathaway Combination tire valve-stem and pressure-gage.
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4816597A (en) * 1983-10-02 1989-03-28 New Jersey Institute Of Technology Dental restorative materials based upon blocked isocyanates
GB8421551D0 (en) 1984-08-24 1984-09-26 Ici Plc Water-soluble dye
DE69632465T2 (de) 1995-06-07 2005-06-23 Ortho-Mcneil Pharmaceutical, Inc. Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung
DE69823046T2 (de) * 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
JP4334141B2 (ja) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
CA2369292C (en) * 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2438148A1 (en) 2001-02-15 2002-08-29 Centocor, Inc. Chemically defined medium for cultured mammalian cells
CN1930288B (zh) * 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
JPWO2003085118A1 (ja) * 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
WO2003084570A1 (en) * 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
JP2006526641A (ja) 2003-05-30 2006-11-24 セントカー・インコーポレーテツド 抗−組織因子抗体を用いる腫瘍成長を抑制する方法
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions

Also Published As

Publication number Publication date
WO2007028106A3 (en) 2009-06-11
KR20080048505A (ko) 2008-06-02
EP1937313A2 (en) 2008-07-02
MX2008003054A (es) 2008-03-25
US20090214528A1 (en) 2009-08-27
JP2009508476A (ja) 2009-03-05
AU2006287224A1 (en) 2007-03-08
BRPI0616600A2 (pt) 2011-06-28
WO2007028106A2 (en) 2007-03-08
EP1937313A4 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
US20230227564A1 (en) Glycosylated antibodies
CA2674239C (en) Methods and vectors for generating asialylated immunoglobulins
JP7765397B2 (ja) 新規抗ｌｉｌｒｂ４抗体および派生産物
JP6840908B1 (ja) エフェクター機能が除去されたＩｇＧ１ Ｆｃ変異体
CA2614046C (en) Methods of controlling properties of therapeutic proteins, fc-containing therapeutic proteins of the g2s2 alpha-(2,3)-sialylated glycoform, and uses thereof
US20210155711A1 (en) Antibody Fc Mutants with Ablated Effector Functions
US20090214528A1 (en) Host cell lines for production of antibody constant region with enhanced effector function
HK1220228A1 (zh) 用於控制蛋白质中的岩藻糖基化水平的方法
US20230400467A1 (en) Pvrl2 and/or pvrig as biomarkers for treatment
CN101627111A (zh) 用于生产具有增强的效应子功能的抗体恒定区的宿主细胞系

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140711